Shingles Vaccine Cuts Heart Risk Nearly in Half: UC Riverside Study Reveals Major Benefits

Breakthrough UC Riverside Study Reveals Shingles Vaccine's Cardioprotective Power

A groundbreaking study from the University of California, Riverside School of Medicine has uncovered a remarkable benefit of the shingles vaccine beyond its primary role in preventing the painful rash known as herpes zoster. Researchers found that adults with existing heart disease who received the vaccine experienced nearly half the rate of serious cardiac events in the year following vaccination compared to unvaccinated peers. This discovery, presented at the American College of Cardiology's Annual Scientific Session (ACC.26) in March 2026, highlights how university-led research is advancing public health by revealing unexpected protective effects of established vaccines.

The study underscores the critical role of U.S. academic institutions in leveraging large-scale health data to inform clinical practice. Led by Robert Nguyen, MD, a resident physician at UC Riverside, the research analyzed records from over 246,000 patients, demonstrating the vaccine's potential to reduce major adverse cardiac events (MACE) by 46%, all-cause mortality by 66%, heart attacks by 32%, strokes by 25%, and heart failure by 25%. These findings build on prior university studies linking shingles prevention to lower cardiovascular risks.

Understanding Shingles: The Varicella-Zoster Virus and Its Hidden Dangers

Shingles, or herpes zoster, results from the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox in childhood. After initial infection, VZV remains dormant in nerve tissues, potentially reactivating decades later due to waning immunity, stress, or age-related immune decline. Affecting about one in three Americans over their lifetime, shingles causes a painful, blistering rash typically on one side of the body, often accompanied by nerve pain called postherpetic neuralgia.

Recent university research has illuminated how VZV reactivation triggers systemic inflammation, endothelial dysfunction, and thrombosis—processes that damage blood vessels and promote clot formation near the heart and brain. Studies from institutions like Harvard Medical School and Stanford University have shown shingles infection elevates heart attack and stroke risk by 30-41% in the following weeks to months. This inflammatory cascade explains why preventing shingles through vaccination could safeguard cardiovascular health, particularly in vulnerable populations.

The UC Riverside Study: Rigorous Methods Using Real-World Data

To investigate the shingles vaccine's impact on heart risk reduction, UC Riverside researchers utilized the TriNetX global health research network, a de-identified database aggregating electronic health records from millions of U.S. patients. The cohort included 246,822 adults aged 50 and older diagnosed with atherosclerotic cardiovascular disease (ASCVD)—plaque buildup narrowing arteries—from 2018 to 2025.

Investigators propensity-matched 123,411 vaccinated individuals (receiving at least one dose of Shingrix, the recombinant zoster vaccine, or Zostavax, the live attenuated vaccine) to an equal number of unvaccinated controls based on demographics, comorbidities, and socioeconomic factors like housing stability and education. Outcomes were tracked from one month to one year post-vaccination, adjusting for confounders to isolate the vaccine's effect.

This real-world evidence approach, common in university epidemiology research, provides robust insights into vaccine performance outside controlled trials, complementing randomized studies.

Striking Results: Quantifying the Heart Protection

• Major adverse cardiac events (MACE, including heart attack, stroke, and hospitalization): 46% risk reduction
• All-cause mortality: 66% lower
• Myocardial infarction (heart attack): 32% reduction
• Stroke: 25% lower risk
• Heart failure hospitalization: 25% decrease

These hazard ratios rival lifestyle interventions like smoking cessation, as noted by Dr. Nguyen. For context, ASCVD patients face annual MACE risks of 5-10%; halving that translates to thousands of prevented events nationwide. American College of Cardiology press release.

Shingrix vs. Zostavax: Which Vaccine Offers Superior Protection?

Shingrix (recombinant zoster vaccine, RZV), approved by the FDA in 2017, is the preferred option per CDC guidelines, with over 90% efficacy against shingles in adults 50+. Administered as two intramuscular doses 2-6 months apart, it targets VZV glycoprotein E to stimulate robust T-cell immunity without live virus.

Zostavax, a live attenuated vaccine discontinued in the U.S. in 2020, was less effective (51%) and waned faster. The UC Riverside study included both but reflects real-world use favoring Shingrix. Prior meta-analyses, like one from European Society of Cardiology universities, show RZV associated with 18% CV risk reduction vs. 16% for Zostavax.

U.S. universities continue monitoring long-term outcomes to refine recommendations.

Photo by Markus Winkler on Unsplash

Biological Mechanisms: How Vaccination Prevents CV Damage

Shingles infection induces a cytokine storm and vascular inflammation, damaging endothelium—the artery lining—and promoting platelet aggregation and clots. Research from the National Heart, Lung, and Blood Institute (NHLBI) and universities like Oxford shows VZV can invade vascular cells, triggering thrombosis akin to COVID-19 complications.

Vaccination boosts VZV-specific immunity, averting reactivation and mitigating this cascade. Anti-inflammatory effects may also confer broader benefits, as seen in studies linking vaccines to lower dementia risk via reduced neuroinflammation. UC Riverside's findings align with this, suggesting vaccination as a low-cost CV preventive strategy.

Beyond the Heart: Emerging Links to Dementia Prevention

University research extends shingles vaccine benefits to brain health. A 2025 Welsh study and U.S. analyses report 17-20% lower dementia incidence post-vaccination, with Stanford researchers noting 20% reduced new diagnoses. Vascular dementia drops 50% in some cohorts, per Infectious Diseases Society data.

Mechanisms include curbing VZV's neurotropism and chronic inflammation. As U.S. universities like Harvard Chan School explore, this positions the vaccine as a multi-system protector, vital amid rising dementia rates.

CDC Guidelines and U.S. Vaccination Landscape

The CDC recommends two doses of Shingrix for all adults 50+, regardless of prior shingles or chickenpox, with 68-91% efficacy in immunocompromised. Medicare covers it at no cost; uptake hovers ~30%, per recent data, lower than flu vaccine.

Cost without insurance: ~$400 for series. Side effects are mild (arm soreness, fatigue), resolving in 2-3 days. Universities advocate boosting rates through education, countering misinformation.

U.S. Universities Driving Vaccine Research Innovation

UC Riverside exemplifies how public universities translate big data into actionable insights, training physician-scientists like Dr. Nguyen. Similar efforts at Harvard, Stanford, and Johns Hopkins have mapped VZV-CV links, fueling policy changes.

Higher ed institutions fund trials, educate providers, and address disparities—e.g., lower uptake among minorities noted in prior UC Riverside work. This research bolsters clinical jobs in cardiology and immunology.

Challenges: Access, Equity, and Future Research Directions

Despite evidence, barriers persist: cost for uninsured, access in rural areas, vaccine hesitancy. Universities push equity via community outreach.

Future studies needed: long-term effects beyond year 1, immunocompromised cohorts, mechanistic trials. NIH-funded university consortia will explore synergies with statins or anti-inflammatories.

Photo by CDC on Unsplash

Actionable Insights: Who Should Get Vaccinated Now?

• Adults 50+ with/without heart disease
• Immunocompromised (19+ per CDC)
• Consult providers for interactions

Schedule via primary care or pharmacies. For heart patients, discuss with cardiologists—benefits outweigh mild side effects.

Outlook: Transforming Preventive Cardiology Through Academia

UC Riverside's study heralds a new era where vaccines combat chronic diseases. As U.S. universities pioneer, expect updated guidelines, higher uptake, and lives saved. Explore research careers at clinical research jobs to contribute.